<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The risk of <z:hpo ids='HP_0000726'>dementia</z:hpo> is increased in people with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>This review gives an update on the relation between T2DM and specific <z:hpo ids='HP_0000726'>dementia</z:hpo> subtypes - i.e. <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> - and underlying pathologies </plain></SENT>
<SENT sid="2" pm="."><plain>We will show that while epidemiological studies link T2DM to <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> as well as vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, neuropathological studies attribute the increased <z:hpo ids='HP_0000726'>dementia</z:hpo> risk in T2DM patients primarily to vascular lesions in the brain </plain></SENT>
<SENT sid="3" pm="."><plain>Risk factors for <z:hpo ids='HP_0000726'>dementia</z:hpo> among patients with T2DM are also addressed </plain></SENT>
<SENT sid="4" pm="."><plain>Currently, there is evidence that microvascular complications, <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and severe hypoglycemic events increase <z:hpo ids='HP_0000726'>dementia</z:hpo> risk </plain></SENT>
<SENT sid="5" pm="."><plain>However, for a more complete understanding of risk factors for <z:hpo ids='HP_0000726'>dementia</z:hpo> in T2DM a life time perspective is needed </plain></SENT>
<SENT sid="6" pm="."><plain>This should identify which individuals are at increased risk, what are vulnerable periods in life, and what are windows of opportunity for treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Currently, there are no DM specific treatments for <z:hpo ids='HP_0000726'>dementia</z:hpo>, but we will review observations from clinical trials that tried to prevent <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> through intensified glycemic control and address other clinical implications of the association between T2DM and <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>